Sernova Reschedules its Annual General and Special Meeting of Shareholders to January 10, 2025
Sernova Corp (TSX: SVA) (OTCQB: SEOVF) has rescheduled its annual general and special meeting of shareholders from January 7, 2025, to January 10, 2025, at 1:00pm ET. The postponement is due to a recent postal strike in Canada, which affected the company's ability to mail meeting materials through Canada Post to meet regulatory requirements. The record date remains November 12, 2024.
Shareholders must submit their proxies by 1:00 p.m. ET on January 8, 2025, either through TMX Trust Company, by telephone, or online. The Management Information Circular is available on Sernova's website and SEDAR+ profile.
Sernova Corp (TSX: SVA) (OTCQB: SEOVF) ha riprogrammato la sua assemblea generale annuale e speciale degli azionisti dal 7 gennaio 2025 al 10 gennaio 2025, alle 13:00 ET. Il rinvio è dovuto a uno sciopero postale recente in Canada, che ha influito sulla capacità dell'azienda di inviare il materiale dell'assemblea tramite Canada Post per soddisfare i requisiti normativi. La data di registrazione rimane il 12 novembre 2024.
Gli azionisti devono inviare le loro deleghe entro le 13:00 ET dell'8 gennaio 2025, sia tramite TMX Trust Company, per telefono o online. Il Circolare delle Informazioni di Gestione è disponibile sul sito web di Sernova e nel profilo SEDAR+.
Sernova Corp (TSX: SVA) (OTCQB: SEOVF) ha reprogramado su reunión anual y especial de accionistas del 7 de enero de 2025 al 10 de enero de 2025, a la 1:00 p.m. ET. El aplazamiento se debe a una reciente huelga postal en Canadá, que afectó la capacidad de la empresa para enviar los materiales de la reunión a través de Canada Post para cumplir con los requisitos regulatorios. La fecha de corte sigue siendo el 12 de noviembre de 2024.
Los accionistas deben enviar sus poderes antes de la 1:00 p.m. ET del 8 de enero de 2025, ya sea a través de TMX Trust Company, por teléfono o en línea. El Circular de Información de Gestión está disponible en el sitio web de Sernova y en el perfil de SEDAR+.
Sernova Corp (TSX: SVA) (OTCQB: SEOVF)는 2025년 1월 7일에서 2025년 1월 10일 오후 1시(ET)로 주주 총회 및 특별회의 일정을 변경했습니다. 이번 연기는 최근 캐나다의 우편 파업으로 인해 회사가 규제 요건을 충족하기 위해 캐나다 포스트를 통해 회의 자료를 발송할 수 있는 능력에 영향을 미쳤기 때문입니다. 기록일자는 2024년 11월 12일로 유지됩니다.
주주는 2025년 1월 8일 오후 1시(ET)까지 TMX Trust Company를 통해 전화 또는 온라인으로 위임장을 제출해야 합니다. 경영정보 순환서는 Sernova 웹사이트와 SEDAR+ 프로필에서 확인할 수 있습니다.
Sernova Corp (TSX: SVA) (OTCQB: SEOVF) a reprogrammé son assemblée générale annuelle et spéciale des actionnaires du 7 janvier 2025 au 10 janvier 2025, à 13h00 ET. Ce report est dû à une récente grève postale au Canada, qui a affecté la capacité de l'entreprise à envoyer les documents de la réunion par l'intermédiaire de Canada Post afin de répondre aux exigences réglementaires. La date d'enregistrement demeure le 12 novembre 2024.
Les actionnaires doivent soumettre leurs procurations avant 13h00 ET le 8 janvier 2025, soit par l'intermédiaire de la TMX Trust Company, par téléphone ou en ligne. Le Circular d'Information de Gestion est disponible sur le site Web de Sernova et dans le profil SEDAR+.
Sernova Corp (TSX: SVA) (OTCQB: SEOVF) hat seine Haupt- und Sonderversammlung der Aktionäre vom 7. Januar 2025 auf den 10. Januar 2025 um 13:00 Uhr ET verschoben. Die Verschiebung ist auf einen kürzlichen Poststreik in Kanada zurückzuführen, der die Fähigkeit des Unternehmens beeinträchtigt hat, die Versammlungsunterlagen über Canada Post zu versenden, um die regulatorischen Anforderungen zu erfüllen. Das Stichtagsdatum bleibt der 12. November 2024.
Aktionäre müssen ihre Vollmachten bis zum 8. Januar 2025 um 13:00 Uhr ET entweder über die TMX Trust Company, telefonisch oder online einreichen. Der Informationsrundschreiben für das Management ist auf der Website von Sernova und im SEDAR+-Profil verfügbar.
- None.
- None.
LONDON, Ontario and BOSTON, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company focused on developing its Cell Pouch bio-hybrid organ as a functional cure for type 1 diabetes, today announced that it will hold its annual general and special meeting of shareholders (the “Meeting”) on Friday, January 10, 2025, at 1:00pm ET. Due to the recent postal strike in Canada, the Meeting, which had originally been scheduled to be held on January 7, 2025, at 1:00pm ET, was postponed so that Sernova and its agents are able to complete the mailing of its meeting materials through Canada Post to meet regulatory requirements.
The record date of November 12, 2024, has not changed. To be effective, the Proxy must be duly completed and signed and then deposited with the Corporation’s registrar and transfer agent, TMX Trust Company, P.O. Box 72, Agincourt, Ontario, M1S 0A1, or voted via telephone, or via the internet (online) as specified in the Proxy, no later than 1:00 p.m. (Eastern Time), on January 8, 2025. The Management Information Circular for the meeting is available on the company’s website, www.sernova.com, and on the company's SEDAR+ profile at www.sedarplus.ca.
ABOUT SERNOVA CORP
Sernova Corp. is a clinical-stage company developing regenerative medicine therapeutics combining its Cell Pouch with human donor cells or stem cells to create a bio-hybrid organ. A bio-hybrid organ refers to a medical device designed to be implanted into the human body, where it integrates with existing living tissue to replicate or enhance the function of a natural organ, essentially aiming to restore normal organ function by combining living cells with non-living materials to mimic the properties of the original organ and seamlessly interact with surrounding tissues. This innovative approach aims to deliver a potentially revolutionary treatment for patients with chronic diseases, initially focusing on type 1 diabetes and thyroid disorders.
FOR FURTHER INFORMATION, PLEASE CONTACT:
David Burke VP, Investor Relations (917) 751-5713 Email: David.Burke@sernova.com Website: https://sernova.com/
The TSX has not reviewed this news release and does not accept responsibility for the accuracy or adequacy of this news release.
FORWARD-LOOKING INFORMATION
This press release contains forward-looking statements within the meaning of applicable Canadian securities laws. Forward-looking statements in this press release include our belief that our technology could lead to a functional cure for T1D. With respect to the forward-looking statements contained in this press release, Sernova has made numerous assumptions regarding, among other things: the company’s ability to secure additional financing on reasonable terms, or at all; and the ability to conduct all required preclinical and clinical studies for the company’s Cell Pouch, including the timing and results of those trials. A more complete discussion of the risks and uncertainties facing Sernova appears in Sernova’s Annual Information Form for the year ended October 31, 2023 filed with Canadian securities authorities and available at www.sedarplus.ca, as updated by Sernova’s continuous disclosure filings, which are available at www.sedarplus.ca. All forward-looking statements herein are qualified in their entirety by this cautionary statement, and Sernova disclaims any obligation to revise or update any such forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except as required by law.
FAQ
When is Sernova's (SEOVF) rescheduled annual general meeting in 2025?
Why did Sernova (SEOVF) postpone its January 2025 shareholders meeting?
What is the proxy submission deadline for Sernova's (SEOVF) January 2025 meeting?
What is the record date for Sernova's (SEOVF) January 2025 shareholders meeting?
